OverviewSuggest Edit

Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Employee Ratings4.2
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2020)105,794(+2%)
Job Openings1,573
Revenue (FY, 2020)$48.7 B(+3%)
Share Price (May 2021)CHF80.5
Cybersecurity ratingAMore

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer
Joerg Reinhardt

Joerg Reinhardt

Chairman
Steven Baert

Steven Baert

Chief People & Organization Officer
James Bradner

James Bradner

President of the Novartis Institutes for BioMedical Research (NIBR)
Thomas N. Kendris

Thomas N. Kendris

Ad Interim Chief Legal Officer of Novartis
Karen L. Hale

Karen L. Hale

Chief Legal Officer
Show more

Novartis Office Locations

Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Pratteln, CH
Schweizerhalle, Rheinstrasse 52
Stein, CH
Schaffhauserstrasse 101
Tirana, AL
Rruga Hoxha Tahsim 23
Bir Mourad Raïs, DZ
69 Zone d´Activité Said Hamdine
Show all (185)

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $48.66 b in FY, 2020 which is a 2.6% increase from the previous period.
USD

Revenue (FY, 2020)

48.7b

Revenue growth (FY, 2019 - FY, 2020), %

2.6%

Gross profit (FY, 2020)

33.5b

Gross profit margin (FY, 2020), %

68.9%

Net income (FY, 2020)

8.1b

EBIT (FY, 2020)

10.2b

Market capitalization (14-May-2021)

179.7b

Closing stock price (14-May-2021)

80.5

Cash (31-Dec-2020)

9.7b

EV

208.1b
Novartis's current market capitalization is CHF179.7 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

51.9b47.4b48.7b

Revenue growth, %

6%(9%)3%

Cost of goods sold

17.1b13.2b15.1b

Gross profit

34.8b34.2b33.5b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

12.7b13.2b12.8b11.1b11.8b12.2b12.3b11.3b12.3b

Cost of goods sold

4.1b4.2b4.3b3.0b3.1b3.5b3.3b3.2b3.8b

Gross profit

8.6b9.0b8.5b8.2b8.6b8.7b9.0b8.2b8.5b

Gross profit Margin, %

68%68%66%73%73%72%73%72%69%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

13.3b11.1b9.7b

Accounts Receivable

8.7b8.3b8.2b

Inventories

7.0b6.0b7.1b

Current Assets

35.6b29.5b29.7b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

5.8b12.4b14.0b6.8b10.0b8.4b4.5b5.9b9.0b

Accounts Receivable

8.9b8.8b8.6b7.6b8.0b7.8b8.5b7.6b8.1b

Inventories

7.2b7.1b7.0b5.7b6.1b6.1b6.4b6.9b7.1b

Current Assets

33.1b32.1b34.1b52.4b28.3b26.7b23.1b23.9b29.0b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

12.6b7.1b8.1b

Depreciation and Amortization

6.9b5.8b6.1b

Inventories

(533.0m)(382.0m)(543.0m)

Accounts Payable

309.0m553.0m(324.0m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

2.0b9.8b11.4b1.9b4.0b6.0b2.2b4.0b6.0b

Depreciation and Amortization

4.9b1.4b2.5b3.9b1.4b3.1b

Cash From Operating Activities

2.5b6.5b10.5b2.4b5.5b10.1b2.5b6.5b9.6b

Purchases of PP&E

(359.0m)(690.0m)(1.1b)(282.0m)(561.0m)(918.0m)(237.0m)(475.0m)(754.0m)
USDQ1, 2018

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.9 x
Show all financial metrics

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Major Approvals (US, EU, JP)

20161615

Major Submissions (US, EU, JP)

1424162030

Patients Reached

972 m965 m927 m

Projects Entering Development Pipeline

859
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Company NameDateDeal Size
Vedere BioOctober 29, 2020$280 m
AmblyotechApril 21, 2020
The Medicines CompanyNovember 25, 2019$9.7 b
XiidraMay 09, 2019$1.9 b
Novartis Inflammasome ResearchApril 02, 2019$1.58 b
CellforCureDecember 21, 2018
EndocyteOctober 18, 2018
AveXisApril 09, 2018$8.7 b
Advanced Accelerator ApplicationsOctober 30, 2017$3.9 b
Encore VisionDecember 20, 2016
Show more

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 19.8% from Sandoz and 80.2% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 5.3% from China, 5.8% from Japan , 33.9% from United States, 5.0% from France, 9.3% from Germany and 40.8% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Novartis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Novartis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Novartis Online and Social Media Presence

Embed Graph

Novartis Company Culture

  • Overall Culture

    A+

    84/100

  • CEO Rating

    A+

    80/100

  • Compensation

    A+

    93/100

  • Diversity

    A+

    83/100

Learn more on Comparably

Novartis News and Updates

Worldwide Multiple Myeloma Treatment Industry to 2029 - Players Include Janssen Biotech, Bristol-Myers Squibb and Novartis Among Others

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Corticosteroids Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson …

Global $12.7 Billion Pharmacogenomics Markets to 2026 with Profiles of Abbott Laboratories, GlaxoSmithKline, Johnson & Johnson, Novartis, Oxford Nanopore Technologies and Thermo Fisher Scientific

Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "Global Pharmacogenomics Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

KT, 한국노바티스와 디지털·바이오헬스 사업 협력

KT가 디지털·바이오헬스산업의 디지털전환(DX) 본격화에 나선다. KT(대표 구현모)는 한국노바티스와 서울 종로구 KT 광화문 EAST사옥에서 디지털·바이오헬스 사업 협력을 위한 업무협약(MOU)을 체결했다고 10일 발표했다.

Global Ai In Pharma Market Report 2021: Long-term Forecast to 2025 & 2030 Featuring Novartis, IBM Watson, Microsoft, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Exscientia, and Cyclica

DUBLIN, May 6, 2021 /PRNewswire/ -- The "AI In Pharma Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. This report focuses on Ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in...

Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best correcte…
Show more

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Steven Baert.

  • How many employees does Novartis have?

    Novartis has 105,794 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $48.7 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $459.9 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Bausch + Lomb, Immunomedics and Gilead Sciences.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Fabrikstrasse 2, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Pratteln, Stein, Broomfield and in 165 other locations.

  • How many offices does Novartis have?

    Novartis has 185 offices.